

Client: Sovereign Health and Performance
Sample Name: Semaglutide **Batch#:** SEME124
Report Date: 6/25/2024
Test: Purity


Receipt Date: 6/25/2024
Analysis Date: 6/25/2024
Matrix: Powder
Number of samples: 1

Certificate of Analysis

Purity: 99.7%

Data File	20240625_Semaglutide_LotSEME124.d	Sample Name	Semaglutide
Sample Type	Sample	Position	P2-A6
Instrument Name	Instrument 1	User Name	
Acq Method	PuritydefaultMS2.m	Acquired Time	6/25/2024 3:35:09 PM (UTC-07:00)
IRM Calibration Status	Not Applicable	DA Method	20211216_PIS7_165and211_quad_SCAN_POS_Nowar taDSDPRWV_neat.m
Comment		Info.	
Sample Group		Acquisition Time (Local)	6/25/2024 3:35:09 PM (UTC-07:00)
Stream Name	LC 1		
Acquisition SW Version	6400 Series Triple Quadrupole B.09.00 (B9037.0)		

Chromatograms



Peak List

Time	Area	%Area
6.872 min.	11.37	0.3%
8.138 min.	3441.54	99.7%

Reviewed and Approved By:

Herman Lelie

Herman Lelie Ph.D Director of R&D

Constitution Labs (CL) maintains liability limited to cost of analysis. Interpretation and use of test results are the responsibility of the client. This report relates only to the samples reported above, and may not be reproduced, except in full, without written approval by CL. This is not intended as an endorsement of any product. CL bears no responsibility for sample collection activities or analytical method limitations. Samples are within quality control criteria and met method specifications unless otherwise noted.